Secretin Articles
Repligen in profit for year-ending 2008
23 June 2008
Repligen narrows loss 87% in fiscal 4th-qtr
18 June 2007
Repligen's FY 2005 sees 35% sales rise
6 June 2005
Repligen's secretin fails to show efficacy
14 February 2005
Repligen's RG1068 fails in autism trial
5 January 2004
Pharmagene starts Ph II trial of PGN0052
22 December 2003
Repligen seeks to widen secretin use
3 June 2002
Repligen starts pivotal autism trial
25 February 2002
Repligen optimistic that its novel autism treatment can move forward
25 February 2002
Repligen plans pivotal trials of autism drug
5 November 2001
Repligen extends Ph II secretin trial in autism
21 June 2001
Repligen drug for autism misses mark
5 April 2001
Repligen begins Ph II with secretin in autism
6 April 2000
Autism treatment hope lifts Repligen
12 March 1999
Showing 1-14 of 14 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
